Surgical intervention remains the primary therapeutic modality for both non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC). The core objective is total extirpation of neoplastic tissue while preserving or reconstructing lower urinary tract function. According to the European Association of Urology (EAU) 2024 guidelines, surgical management is categorized into organ-sparing endoscopic resections and radical extirpative operations paired with urinary diversion techniques such as ileal conduits or orthotopic neobladders.

Bladder cancer surgery spans endoscopic and extirpative techniques. Transurethral resection of bladder tumor (TURBT) involves passing a rigid resectoscope through the urethra under regional or general anesthesia. Using a high-frequency electrocautery loop, the surgeon systematically resects visible mucosal tumors down to the detrusor muscle bed to obtain accurate histopathological staging. For muscle-invasive disease, radical cystectomy is performed via open, laparoscopic, or robot-assisted approaches. In male patients, the anterior pelvic organs including the bladder, prostate, seminal vesicles, and distal ureters are resected. In female patients, standard radical cystectomy involves removing the bladder, anterior vaginal wall, uterus, fallopian tubes, ovaries, and distal ureters. A bilateral pelvic lymph node dissection is executed from the aortic bifurcation down to the obturator fossa. Urinary continuity is re-established using a segment of isolated bowel to create an ileal conduit (incontinent diversion), an orthotopic neobladder connected to the native urethra, or a continent cutaneous reservoir.

Surgical resection offers definitive local tumor control and diagnostic grading accuracy. Transurethral resection provides immediate eradication of early-stage tumors while preserving normal bladder function. Radical cystectomy coupled with pelvic lymph node dissection provides the highest rate of long-term local disease control for muscle-invasive bladder cancer, with five-year recurrence-free survival rates established across clinical trial cohorts published by the American Urological Association (AUA) and Society of Urologic Oncology (SUO).

Recovery from transurethral procedures typically requires 1 to 2 weeks, with temporary urinary frequency and mild hematuria. Recovery following radical cystectomy and urinary diversion spans 6 to 12 weeks. Initial hospital stay lasts 4 to 8 days under Enhanced Recovery After Surgery (ERAS) protocols. Full functional adaptation to urinary diversions, such as neobladder training or ostomy management, unfolds over 3 to 6 months.

Bladder cancer surgery treats non-muscle-invasive urothelial carcinoma (Ta, T1, and carcinoma in situ), muscle-invasive urothelial carcinoma (T2, T3, T4a), and rare non-urothelial bladder malignancies such as squamous cell carcinoma, adenocarcinoma, and small cell neuroendocrine carcinoma. It also addresses recurrent mucosal lesions and treatment-refractory disease following intravesical instillations.

Pre-operative evaluation requires flexible cystoscopy, high-resolution computed tomography (CT) urography or magnetic resonance imaging (MRI) of the chest, abdomen, and pelvis to rule out metastatic disease, and baseline blood biochemistry. Patients undergoing radical cystectomy undergo cardiopulmonary risk stratification, nutritional assessment, and pre-operative stoma marking by a certified enterostomal therapist. In accordance with ERAS society guidelines, bowel preparation is minimized or eliminated, carbohydrate loading is administered prior to surgery, and prophylactic antibiotics and low-molecular-weight heparin are initiated to lower infection and thromboembolism risks.

Transurethral resection risks include transient macroscopic hematuria, urinary tract infection, bladder spasm, acute urinary retention, and rarely, intraperitoneal or extraperitoneal bladder perforation (<2%). Radical cystectomy risks are categorized into early and late complications. Early risks (within 30 days) include surgical site infection, paralytic ileus, deep vein thrombosis, pulmonary embolism, ureteroenteric anastomotic leak, and sepsis. Late complications (after 30 days) include metabolic acidosis, Vitamin B12 deficiency, stomal stenosis, ureteral stricture, parastomal hernia, chronic urinary tract infections, renal deterioration, and erectile dysfunction or sexual dysfunction due to pelvic nerve damage.

The clinical journey begins with diagnostic workup including flexible cystoscopy, cross-sectional imaging, and urine cytology. Patients undergo pre-operative risk stratification and optimization. Surgical execution varies from day-surgery endoscopic resection to major open or robotic radical cystectomy requiring multi-day hospitalization. Post-operative management focuses on urinary output monitoring, pain management, early mobilization, and stoma or neobladder rehabilitation, followed by routine oncological surveillance.